Flow Pharma, a San Francisco Bay Area biotech, has formed a China JV with Button Capital to conduct China clinical trials of its therapeutic cancer vaccines. Button is a Silicon Valley-based investor that supports companies around the globe. Flow uses artificial intelligence to select neoantigen peptide targets on cancer cells or virus-infected cells, which are then targeted by the patient’s own immune system. The peptides are loaded into the FlowVax synthetic therapeutic vaccine platform. The company’s initial product is a pre-clinical HPV vaccine to treat cervical cancer.
Source: China Biotoday
